Biopharma

Heart Failure With Preserved Ejection Fraction (HFpEF): Pipeline Overview

Despite the long list of clinical trial failures in HFpEF, several promising drugs are in Phase III trials Despite heart failure with preserved ejection fraction (HFpEF) accounting for approximately half of all chronic heart failure (CHF) cases, and despite our improved understanding of the pathophysiology, pharmacological treatments with proven outcomes benefits in HFpEF have proved […]

71% of surveyed MCOs have outcomes-based contracts with pharma or plan to by the end of 2019

Outcomes-based contracting (OBC) is a growing value-based purchasing strategy used by U.S. healthcare payers to hold pharmaceutical companies responsible for ensuring that their drugs perform according to expectations in a real-world patient setting. Key finding: OBCs are increasingly embraced by payers, with 71% of surveyed pharmacy and medical directors from managed care organizations (MCOs) reporting […]

Neuroscience lures dealmakers despite drug development challenges

While no other therapeutic area matches oncology in dealmaking volume, neurology is “among the nearest contenders.” That’s the main theme of recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Trends in Neuroscience Dealmaking,” was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, […]

Top Seven Predictions for PBM industry in 2019

While 2018 was a busy year for pharmacy benefit managers making waves, 2019 looks no different. Vertical integration will undoubtedly remain the key driver for transformation as both the mega-mergers of CVS/Aetna and Cigna/Express Scripts are now completed. These combined healthcare powerhouses are poised to bring some major changes in the outlook of pharmacy benefit […]

Challenges in SLE Drug Development: The Key Hurdles

Systemic Lupus Erythematosus (SLE) is an autoimmune condition characterized by the production of pathogenic autoantibodies and tissue deposition of immune complexes. The disease is extremely heterogeneous in nature—which often leads to delays in diagnosis—although it most commonly affects the musculoskeletal and mucocutaneous systems. The disruption of normal functioning of other organs, such as the kidneys, […]

How regulation, innovation, quality and access are inevitably intertwined

In a global industry like pharmaceuticals, the interdependencies among quality, access, innovation and regulation can have global implications. That message comes through clearly in the 2018 CPhI Annual Report, the compilation of expert forecasts and analyses that the organization puts together. The articles, with their focus on the future direction, technologies, opportunities and threats in […]

Mutual Self-Interest: Joint Venture Payer-Provider Health Plans

As large hospital systems have amassed greater power in their markets through mergers, developing regional integrated delivery networks and starting ACOs, health plans and providers have had to re-think the old oppositional relationship between payers and providers. The last decade’s evolution of performance-based payments and value-based care, together with the technology and systems that make […]

Roche’s Hemlibra: Market expansion approved, but safety an initial concern?

The annual industry forecast and analysis report Drugs to Watch from Clarivate Analytics was published in March 2018, detailing the pharma industry’s expected blockbuster launches for 2018. The report was led by Roche/Chugai’s hemophilia drug Hemlibra (emicizumab), for which analysts had very big expectations, and consensus forecasts stood at $4.002 billion for 2022 at the […]

Predictive analytics yield smarter pharma portfolio decisions

Collecting competitive data isn’t the problem; most biopharma companies are drowning in it. But making sense of the data, using it to predict likely shifts in the competitive landscape and drive decisions can be a challenge. While forecasting drug timelines and success rates are critical to inform investment and R&D decisions, the standard approach has […]

CV Risk: Vascepa Doesn’t just REDUCE-IT, Vascepa Slashes it

I must admit it, I am surprised by the scale of the risk reduction that Amarin Corporation’s Vascepa (icosapent ethyl) has delivered in the REDUCE-IT cardiovascular outcomes trial (CVOT).   REDUCEd-IT and more In this trial of more than 8,000 statin-treated primary and secondary CV prevention patients with moderately raised triglyceride (TGs) levels, Vascepa was […]